Literature DB >> 15142340

Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.

Koichi Yokogawa1, Mingji Jin, Naho Furui, Masaru Yamazaki, Hiromi Yoshihara, Masaaki Nomura, Hiroyuki Furukawa, Junko Ishizaki, Sachio Fushida, Kouichi Miwa, Ken-ichi Miyamoto.   

Abstract

Rats were intraperitoneally administered 40 mg x kg(-1) of paclitaxel or docetaxel dissolved in various drug solutions. The drug solutions were prepared using 20 mL of saline, adding 4.2% Cremophor EL (crEL) for paclitaxel (TXL), and 1.5% Polysorbate-80 (PS-80) (TXT), 7.5% PS-80 (TXT+PS-80) or 4.2% crEL (TXT+crEL) for docetaxel. The apparent first-order absorption rate constant from the peritoneal cavity (k(a)) of TXL was about one-twentieth of that of TXT. The ratio of the area under the concentration-time curve of drug in plasma over that in ascites for TXL was about one-third of that of TXT. The values of the above ratio and the k(a) of TXT+PS-80 and TXT+crEL were similar to those of TXL. After intraperitoneal administration, the values of the blood-to-plasma concentration ratio in the four groups were similar and independent of time. In the in-vitro study, PS-80 and crEL caused similar, concentration-dependent decreases of drug permeation into red blood cells after a 15-min incubation of rat blood with 10 microg x mL(-1) of TXL. We demonstrated that the disposition kinetics of taxanes after intraperitoneal administration to rats was strongly influenced, in a concentration-dependent manner, by the surfactant vehicle used, crEL or PS-80.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142340     DOI: 10.1211/0022357023303

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

1.  Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease.

Authors:  Diane E Milenic; Kayhan Garmestani; Erik D Brady; Kwamena E Baidoo; Paul S Albert; Karen J Wong; Joseph Flynn; Martin W Brechbiel
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

2.  The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice.

Authors:  Joanna E Fardell; Ji Zhang; Raquel De Souza; Janette Vardy; Ian Johnston; Christine Allen; Jeffrey Henderson; Micheline Piquette-Miller
Journal:  Psychopharmacology (Berl)       Date:  2013-10-08       Impact factor: 4.530

3.  Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel.

Authors:  Max Tsai; Ze Lu; Jie Wang; Teng-Kuang Yeh; M Guillaume Wientjes; Jessie L-S Au
Journal:  Pharm Res       Date:  2007-04-20       Impact factor: 4.200

4.  Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model.

Authors:  Joji Kitayama; Hironori Ishigami; Hironori Yamaguchi; Jun Yamada; Daisuke Soma; Hideyo Miyato; Takao Kamei; Alan Kawarai Lefor; Naohiro Sata
Journal:  Pleura Peritoneum       Date:  2017-03-30

Review 5.  Current status of conversion surgery for stage IV gastric cancer.

Authors:  Jun Kinoshita; Takahisa Yamaguchi; Hideki Moriyama; Sachio Fushida
Journal:  Surg Today       Date:  2021-01-23       Impact factor: 2.549

6.  Disposition kinetics of taxanes in peritoneal dissemination.

Authors:  Ken'ichi Miyamoto; Tsutomu Shimada; Kazuki Sawamoto; Yoshimichi Sai; Yutaka Yonemura
Journal:  Gastroenterol Res Pract       Date:  2012-05-16       Impact factor: 2.260

Review 7.  Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent.

Authors:  L De Smet; W Ceelen; J P Remon; C Vervaet
Journal:  ScientificWorldJournal       Date:  2013-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.